Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Magyar Onkologia|April 10, 2007
[Human recombinant erythropoietin-alpha increases the efficacy of irradiation in preclinical model]József Lövey, István Kenessey, Erzsébet Rásó, et al.Cancer Immunology, Immunotherapy : CII|July 23, 2011
Prognostic impact of B-cell density in cutaneous melanomaAndrea Ladányi, Judit Kiss, Anita Mohos, et al.European Journal of Medicinal Chemistry|January 3, 2016
Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cellsRita Garamvölgyi, Judit Dobos, Anna Sipos, et al.Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|January 12, 2008
Recombinant human erythropoietin alpha improves the efficacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvesselsJózsef Lövey, Bíborka Bereczky, Réka Gilly, et al.Cancer Research|July 20, 2006
Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancerBalazs Dome, Jozsef Timar, Judit Dobos, et al.Pathology Oncology Research : POR|March 10, 2015
Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS MutationsTamás Garay, Eszter Molnár, Éva Juhász, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 7, 2017
Optimized conversion of antiproliferative lignans pinoresinol and epipinoresinol: Their simultaneous isolation and identification by centrifugal partition chromatography and high performance liquid chromatographyAnna Sólyomváry, Ágnes Alberti, András Darcsi, et al.Oncotarget|September 17, 2019
Targeted drug combination therapy design based on driver genesLilian Zsákai, Anna Sipos, Judit Dobos, et al.Plos One|February 4, 2015
Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cellsTamás Garay, István Kenessey, Eszter Molnár, et al.Bioorganic & Medicinal Chemistry Letters|January 14, 2018
Novel compounds with potent CDK9 inhibitory activity for the treatment of myelomaZsófia Czudor, Mária Balogh, Péter Bánhegyi, et al.Pageof 3